TROG 02.03 - BLADDER (Phase III) - TROG Cancer Research

By w.paterson
23 June, 2021
0 Comments

Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder

Primary Sponsor

Urological Society of Australasia

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

Trial Chairperson

Dr Kumar Gogna, QRI Mater Centre, QLD

Trial Contact

Kumar Gogna

Clinical Trial Registration

Registration Link

15 July, 2025

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

TRIAL UPDATE: 15 July 2025 The TROG 20.01 CHEST-RT

8 July, 2025

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder

TROG 03.01 – Oesophagus

TROG 11.A – ANROTAT

Related Post

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial